Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Phase 1 Unknown 30 enrolled Association Tunisienne de lutte Contre le Cancer Hoffmann-La Roche · collab Sanofi · collab

NaSingle-groupOpen-labelTreatment

Summary

Multi-center, non randomised, open label, non controlled pilot study. Evaluating the treatment of bevacizumab in association with pre-operative chemotherapy, followed by surgery, adjuvant chemotherapy and radiotherapy in Patients with inflammatory breast cancer.

Timeline

Start: 2011-03
Primary completion: 2013-09
Completion: 2017-04

Publications

Background Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006 Feb 10;24(5):769-77. doi: 10.1200/JCO.2005.03.4645. Epub 2006 Jan 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	—
Background	Cyclophosphamide	Other / unclassified	500 mg/m2	—
Background	Docetaxel	Small molecule	100 mg/m2	—
Background	Epirubicin	Small molecule	100 mg/m2	—
Background	Trastuzumab	Monoclonal antibody	6 mg/kg	—
Background	fluorouracil	Small molecule	500 mg/m2	—

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Summary

Timeline

Publications

Drugs

Indications